A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease

Completed · Phase 3

Conditions studied: Dry Eye Syndromes

In brief

This study will evaluate the safety and efficacy o fRefresh Optive® Gel Drops in patients with dry eye disease.

Key facts

Study ID

NCT02280473

Run by

Allergan

People needed

188

Starts

2014-11-13

Expected to finish

2015-03-16

Last updated by the study team

2019-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Current use of an artificial tear product
• Visual acuity of at least 20/32 (while wearing glasses, if necessary).

You may not qualify if…

• Use of contact lenses in the last 3 months, or anticipated use of contact lenses during the study
• Cataract surgery, laser-assisted in situ keratomileusis [LASIK], or photorefractive keratectomy, within the last 6 months
• Current eye infection or inflammation

Where it is running

• North Bay Eye Associates — Petaluma, California, United States
• Eric M. White, OD, Inc. — San Diego, California, United States
• Eye Center Northeast — Bangor, Maine, United States
• Moyes Eye Center, PC — Kansas City, Missouri, United States
• Ophthalmology Associates — St Louis, Missouri, United States
• Comprehensive Eye Care, Ltd. — Washington, Missouri, United States
• Rochester Ophthalmological Group, PC — Rochester, New York, United States
• David W. Ferris & Associates, Inc. — Warwick, Rhode Island, United States
• Primary Eyecare Group, PC — Brentwood, Tennessee, United States
• The Eye Center at Southern College of Optometry — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.